ArticleBiotechnology reports (Amsterdam, Netherlands)2022
Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds.
Article in Biotechnology reports (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 80 citations in OpenAlex.
- Resilience of recombinant antibiotic resistance gene-containing plasmids against common cell culture disposal methods.Cell reports methods · 2026Article
- Biofilm Control with Rare-Earth Oxides: A Mechanistic Framework for Next-Generation Antibiofilm Materials.Nanomaterials (Basel, Switzerland) · 2026Review
- Nano-Enabled Delivery of Phage-Based Antibacterials Against ESKAPE Pathogens.Pharmaceutics · 2026Review
- Comprehensive genomic analysis of multidrug-resistantFrontiers in microbiology · 2026Article
- WHO priority pathogens, ESKAPE bacteria, and antimicrobial resistance surveillance in household wastewater, Gombe, Nigeria.Access microbiology · 2026Article
- Characterization of Natural Products as Inhibitors of Shikimate Dehydrogenase from Methicillin-ResistantBiomolecules · 2025Article
- Prevalence and antibiotic resistance profiles of ESKAPE pathogens in the neonatal intensive care unit of the women and newborn hospital in Lusaka, Zambia.Antimicrobial resistance and infection control · 2025Article
- Antimicrobial and Antiradical Activity of Extracts from Leaves of Various Cultivars ofBiomolecules · 2025Article
- Gram-positive ESKAPE pathogens in Germany: A comprehensive analysis of occurrence and resistance development in animal, food, and environmental sources.One health (Amsterdam, Netherlands) · 2025Review
- Newly isolated terpenoids (covering 2019-2024) from Aspergillus species and their potential for the discovery of novel antimicrobials.Natural products and bioprospecting · 2025Review
- Unseen Enemy: Mechanisms of Multidrug Antimicrobial Resistance in Gram-Negative ESKAPE Pathogens.Antibiotics (Basel, Switzerland) · 2025Review
- Microbial Siderophores: A New Insight on Healthcare Applications.BME frontiers · 2025Review
- Discovery of triazole derivatives for biofilm disruption, anti-inflammation and metal ion chelation.Frontiers in chemistry · 2025Article
- Evaluating Anti-Journal of pharmacy & bioallied sciences · 2024Article
- Antimicrobial Resistance: What Lies Beneath This Complex Phenomenon?Diagnostics (Basel, Switzerland) · 2024Review
- Genomic Analysis ofAntibiotics (Basel, Switzerland) · 2024Article
- 3-Substituted Coumarins Inhibit NorA and MepA Efflux Pumps ofAntibiotics (Basel, Switzerland) · 2023Article
- Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities.Cancer metastasis reviews · 2023Review
- Phytochemicals as Invaluable Sources of Potent Antimicrobial Agents to Combat Antibiotic Resistance.Life (Basel, Switzerland) · 2023Review
- Green synthesis of MgO nanoparticles and its antibacterial properties.Frontiers in chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microorganisms that have developed resistance to available therapeutic agents are threatening the globe and multidrug resistance among the bacterial pathogens is becoming a major concern of public health worldwide. Bacteria develop protective mechanisms to counteract the deleterious effects of antibiotics, which may eventually result in loss of growth-inhibitory potential of antibiotics. ESKAPE (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.